 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || sequential different B cell antigen-targeted CAR T-cell therapy / Beijing Boren Hospital
Clinical, Journal, CAR T-Cell Therapy: Sequential different B cell antigen-targeted CAR T-cell therapy for pediatric refractory/relapsed Burkitt Lymphoma. (Pubmed Central) - Apr 12, 2022
Patients with CNS involvement may benefit from sequential CAR T-cell therapy. This trial was registered at www.chictr.org.cn/index.aspx as ChiCTR1800014457.
- sequential different B cell antigen-targeted CAR T-cell therapy / Beijing Boren Hospital
Efficacy and Safety of Sequential Different B Cell Antigen-Targeted CAR T-Cell Therapy for Pediatric Refractory/Relapsed Burkitt Lymphoma with Secondary Central Nervous System Involvement (GWCC - Hall A1) - Nov 5, 2021 - Abstract #ASH2021ASH_1568;
CONCLUSION S equential CAR T-cell therapy may result in a durable response and is safe in pediatric r/r Burkitt lymphoma. Patients with secondary CNS involvement may benefit from s equential CAR T-cell therapy.